论文部分内容阅读
目的:研究Cox-2、P504s、CK34βE12和P63在前列腺腺癌组织中的表达及其临床病理学意义。方法:用免疫组织化学法检测134例正常前列腺、良性前列腺增生和前列腺腺癌石蜡包埋组织中Cox-2、P504s、CK34βE12和P63的表达。结果:正常前列腺组织或良性前列腺增生组织未见或偶见P504s弱表达,但CK34βE12和P63均表达良好;前列腺腺癌组织中P504s表达良好,但CK34βE12和P63均表达消失,P504s表达阳性率为91.07%;与正常前列腺组和良性前列腺增生组相比,前列腺癌组的P504s阳性表达率存在显著性差异(p=0.001)。COX-2在正常的前列腺组织几乎不表达,而良性前列腺增生组织及前列腺腺癌组织均可见阳性表达,阳性率分别为4.76%和80.36%;COX-2阳性表达率在正常前列腺组或良性前列腺增生组和前列腺腺癌组间有显著性差异(p=0.0027)。COX-2与P504s表达存在相关性(r=0.377,P=0.039);COX-2的表达与年龄、临床分期、分化程度、有无远处转移等临床病理特征间无明显相关关系。结论:联合P504s、P63、CK34βE12和COX-2免疫组化检测可提高前列腺腺癌病理诊断的准确率。
Objective: To investigate the expression of Cox-2, P504s, CK34βE12 and P63 in prostatic adenocarcinoma and their clinicopathological significance. Methods: The expressions of Cox-2, P504s, CK34βE12 and P63 in paraffin-embedded tissues of 134 normal prostate, benign prostatic hyperplasia and prostatic adenocarcinoma were detected by immunohistochemistry. Results: P504s was weakly expressed in normal prostate or benign prostatic hyperplasia tissues, but CK34βE12 and P63 were well expressed. P504s in prostate adenocarcinoma was well expressed, but both CK34βE12 and P63 disappeared, and the positive rate of P504s was 91.07 %. Compared with normal prostate and benign prostatic hyperplasia group, the positive expression rate of P504s in prostate cancer group was significantly different (p = 0.001). COX-2 was almost not expressed in normal prostate tissue, but positive in benign prostatic hyperplasia and prostatic adenocarcinoma, the positive rates were 4.76% and 80.36%, respectively. The positive rate of COX-2 in normal prostate or benign prostatic There was a significant difference between the proliferative and prostatic adenocarcinoma groups (p = 0.0027). The expression of COX-2 was correlated with the expression of P504s (r = 0.377, P = 0.039). There was no significant correlation between the expression of COX-2 and clinicopathologic features such as age, clinical stage, differentiation and distant metastasis. Conclusion: The combination of P504s, P63, CK34βE12 and COX-2 immunohistochemistry can improve the accuracy of pathological diagnosis of prostatic adenocarcinoma.